Stock Research for ARQL


Featured Broker: Ally Invest

Get the due diligence for another stock.


ARQL Stock Chart & Research Data

The ARQL chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ARQL chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


ARQL Due diligence Resources & Stock Charts

The ARQL stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ARQL Detailed Price Forecast - CNN Money CNN View ARQL Detailed Summary - Google Finance
Yahoo View ARQL Detailed Summary - Yahoo! Finance Zacks View ARQL Stock Research & Analysis -

Stock Analysis

TradeIdeas View ARQL Trends & Analysis - Trade-Ideas Barrons View ARQL Major Holders - Barrons
NASDAQ View ARQL Call Transcripts - NASDAQ Seeking View ARQL Breaking News & Analysis - Seeking Alpha
Spotlight View ARQL Annual Report - OTC Report View ARQL OTC Short Report -
TradeKing View ARQL Fundamentals - TradeKing Charts View ARQL SEC Filings - Bar Chart
WSJ View Historical Prices for ARQL - The WSJ Morningstar View Performance/Total Return for ARQL - Morningstar
MarketWatch View the Analyst Estimates for ARQL - MarketWatch CNBC View the Earnings History for ARQL - CNBC
StockMarketWatch View the ARQL Earnings - StockMarketWatch MacroAxis View ARQL Buy or Sell Recommendations - MacroAxis
Bullish View the ARQL Bullish Patterns - American Bulls Short Pains View ARQL Short Pain Metrics -

Social Media Mentions

StockTwits View ARQL Stock Mentions - StockTwits PennyStocks View ARQL Stock Mentions - PennyStockTweets
Twitter View ARQL Stock Mentions - Twitter Invest Hub View ARQL Investment Forum News - Investor Hub
Yahoo View ARQL Stock Mentions - Yahoo! Message Board Seeking Alpha View ARQL Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for ARQL - Insider Cow View Insider Transactions for ARQL - Insider Cow
CNBC View ARQL Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ARQL - OTC Markets
Yahoo View Insider Transactions for ARQL - Yahoo! Finance NASDAQ View Institutional Holdings for ARQL - NASDAQ

Stock Charts

FinViz View ARQL Stock Insight & Charts - StockCharts View ARQL Investment Charts -
BarChart View ARQL Stock Overview & Charts - BarChart Trading View View ARQL User Generated Charts - Trading View

Latest Financial News for ARQL

Wired News – ArQule Inked Exclusive License Deal with Basilea for Derazantinib in the US, EU, Japan and Rest of World
Posted on Thursday April 19, 2018

Stock Monitor: Hemispherx Biopharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 19, 2018 / has just released a free research report on ArQule, Inc. (NASDAQ: ARQL ). If ...

Benzinga Pro's 5 Stocks To Watch Today
Posted on Tuesday April 17, 2018

Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Netflix, Inc. (NASDAQ: NFLX ) shares gained around ...

ArQule and Basilea Enter into Exclusive License Agreement for Derazantinib in the US, EU, Japan and Rest of World Excluding Greater China
Posted on Tuesday April 17, 2018

ArQule, Inc. today announced that it has entered into an exclusive license agreement with Basilea Pharmaceutica International Limited to develop and commercialize derazantinib, a pan-FGFR inhibitor in the US, EU, Japan and rest of the world excluding the People’s Republic of China, Hong Kong, Macau and Taiwan, where Sinovant Sciences Ltd., a Roivant Sciences Ltd.

Basilea licenses late-stage oncology drug candidate derazantinib from ArQule
Posted on Monday April 16, 2018

Basel, Switzerland, April 17, 2018 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that it has entered into a license agreement with ArQule, Inc. (NASDAQ: ARQL) for its oncology drug candidate ...

Enter a stock symbol to view the stock details.